Cover

Investor Presentation / May 2016 / www.admedus.com

Investor

Presentation

May 2016

Disclaimer

This presentation is the property of Admedus Ltd ("Admedus"). This presentation is not and does not constitute an offer, invitation or recommendation to subscribe for, or purchase any security and neither this presentation nor anything contained in it shall form the basis of any contract or commitment.

This presentation does not constitute an offer, solicitation or invitation in any, state or jurisdiction anywhere, or to any person to whom, such an offer or sale would be unlawful. This presentation is not intended as an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the United States or to any person to whom it is unlawful to make such an offer, invitation or solicitation. Reliance should not be placed on the information or opinions contained in this presentation. This presentation does not take into consideration the investment objectives, financial situation or particular needs of any particular investor. Any decision to purchase or subscribe for securities in Admedus must be made solely on the basis of the information contained in the public domain and if necessary after seeking appropriate financial and legal advice.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, Admedus and its affiliates and related bodies corporate, and their respective officers, directors, employees and agents disclaim any liability (including, without limitation, any liabilities arising from fault or negligence) for any loss arising from any use of this presentation (or its content) or otherwise arising in connection with it. Admedus' forward-looking statements, intentions, forecasts, prospects, returns, expectations, statements in relation to future matters or other forward looking statement contained in this presentation may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. They are based on a number of estimates, assumptions that are subject to business, scientific, economic and competitive uncertainties and contingencies, with respect to future business decisions, which are subject to change and, in many cases, are outside the control of Admedus and its directors. Neither Admedus nor its directors give any assurance that the forecast performance in the forecasts or any forward-looking statement contained in this presentation will be achieved.

This presentation is not an offer of securities for sale in the United States. The securities may not be offered or sold in the United States unless they are registered or exempt from registration. Any public offering of securities to be made in the United States will be made by means of a prospectus that will contain detailed information about the company and management, as well as financial statements.

Investor Presentation / May 2016 / www.admedus.com

Investor Presentation / May 2016 / www.admedus.com

Presentation Overview

  • Company overview

  • 4C summary

  • Strategic Outlook

  • CardioCel and ADAPT

  • Immunotherapies

  • Milestones

    Investor Presentation / May 2016 / www.admedus.com

    Sales & Distribution

    • Established sales infrastructure

    • Infusion, surgery and cardiac hospital markets

    • Growing revenue

BUSINESS MODEL

Regenerative Tissue

  • Regenerative tissue product pipeline

  • Product approved for sale and generating revenue

  • Proprietary ADAPT tissue engineering technology

    Immunotherapies

    • Next generation immunotherapies in HPV and herpes

    • Progressing through

      clinical trials

    • Commercialising Ian Frazer's DNA vaccine technology

      Biomanufacturing

    • R&D infrastructure and hub for future products

    • Scale up of manufacturing

    • State of the art facility

Investor Presentation / May 2016 / www.admedus.com

Admedus Ltd. issued this content on 03 May 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 02 May 2016 23:48:01 UTC. Original document available at http://clients2.weblink.com.au/clients/admedus/article.asp?asx=AHZ&view=6762530